RELATED PARTIES	6 Months Ended
Jun. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	RELATED PARTIES The Company's equity method investees primarily consist of its clinical trials central laboratory services joint venture and its diagnostic information services joint ventures, which are accounted for under the equity method of accounting. During the three months ended June 30, 2018 and 2017, the Company recognized net revenues of $9 million and $11 million, respectively, associated with diagnostic information services provided to its equity method investees. During the six months ended June 30, 2018 and 2017, the Company recognized net revenues of $18 million and $20 million, respectively, associated with such services. As of both June 30, 2018 and December 31, 2017, there was $3 million of accounts receivable from equity method investees related to such services. During the three months ended June 30, 2018 and 2017, the Company recognized income of $4 million and $5 million, respectively, associated with the performance of certain corporate services, including transition services, for its equity method investees, classified within selling, general and administrative expenses. During the six months ended June 30, 2018 and 2017, the Company recognized income of $8 million and $9 million, respectively, associated with the performance of such services classified within selling, general and administrative expenses. As of June 30, 2018 and December 31, 2017, there was $3 million and $7 million, respectively, of other receivables from equity method investees included in prepaid expenses and other current assets related to these service agreements and other transition related items. In addition, accounts payable and accrued expenses as of December 31, 2017 included $1 million due to equity method investees. During the three months ended June 30, 2018, the Company contributed $10 million to an equity method investee to fund its share of an acquisition made by the equity method investee.

RELATED PARTIES

The Company's equity method investees primarily consist of its clinical trials central laboratory services joint venture and its diagnostic information services joint ventures, which are accounted for under the equity method of accounting. During the three months ended June 30, 2018 and 2017, the Company recognized net revenues of $9 million and $11 million, respectively, associated with diagnostic information services provided to its equity method investees. During the six months ended June 30, 2018 and 2017, the Company recognized net revenues of $18 million and $20 million, respectively, associated with such services. As of both June 30, 2018 and December 31, 2017, there was $3 million of accounts receivable from equity method investees related to such services.

During the three months ended June 30, 2018 and 2017, the Company recognized income of $4 million and $5 million, respectively, associated with the performance of certain corporate services, including transition services, for its equity method investees, classified within selling, general and administrative expenses. During the six months ended June 30, 2018 and 2017, the Company recognized income of $8 million and $9 million, respectively, associated with the performance of such services classified within selling, general and administrative expenses. As of June 30, 2018 and December 31, 2017, there was $3 million and $7 million, respectively, of other receivables from equity method investees included in prepaid expenses and other current assets related to these service agreements and other transition related items. In addition, accounts payable and accrued expenses as of December 31, 2017 included $1 million due to equity method investees.

During the three months ended June 30, 2018, the Company contributed $10 million to an equity method investee to fund its share of an acquisition made by the equity method investee.